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S
elective loss of neurons, abnormal pro-
tein deposition and neuroinflamma-
tion are the common pathological features 
of neurodegenerative diseases, and these 
features are closely related to one another. 
In Parkinson’s disease, abnormal aggre-
gation and deposition of α-synuclein is 
known as a critical event in pathogenesis of 
the disease, as well as in other related neu-
rodegenerative disorders, such as demen-
tia with Lewy bodies and multiple system 
atrophy. Increasing evidence suggests 
that α-synuclein aggregates can activate 
glial cells to induce neuroinflammation. 
However, how an inflammatory micro-
environment is established and main-
tained by this protein remains unknown. 
Findings from our recent study suggest 
that neuronal α-synuclein can be directly 
transferred to astrocytes through sequen-
tial exocytosis and endocytosis and induce 
inflammatory responses from astrocytes. 
Here we discuss potential roles of astro-
cytes in a cascade of events leading to 
α-synuclein-induced neuroinflammation.
Astrocytes, which are the most abundant 
cells in the brain, are responsible for a wide 
variety of important functions, including 
regulation of blood flow, maintenance of 
the blood-brain barrier (BBB), synaptic 
function and plasticity and maintenance of 
the extracellular environment of ions, flu-
ids and neurotransmitters.1,2 Insults to the 
central nervous system (CNS) from injury 
and disease could result in molecular, 
cellular and functional changes in astro-
cytes, leading to what is known as ‘reactive 
astrogliosis’, which is epitomized by an 
alteration in gene expression, hypertrophy 
and proliferation of astrocytes. Known 
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molecular triggers of reactive astrogliosis 
include peptide growth factors and cyto-
kines, such as FGF2, IL-6, TNFα and 
IL-1, neurotransmitters such as glutamate 
and noradrenalin and disease-associated 
products, such as β-amyloid and these fac-
tors could be released by all cell types of 
CNS, including neurons, microglia, oli-
godendrocytes, endothelia and astrocytes.
The role of reactive astrogliosis has been 
controversial. Neurotoxicity, inflamma-
tion and inhibition of axon regeneration 
are some of the negative impacts of reac-
tive astrogliosis that have been depicted for 
many years. However, findings from recent 
studies also support the role of reactive 
astrogliosis in protection of brain cells. The 
protective roles of reactive astrocytes are 
implicated by uptake of glutamate, gluta-
thione production, protection from NH4+ 
toxicity, degradation of neurotoxic amyloid 
β-peptides, blood brain barrier repair and 
limiting inflammatory cells and infectious 
agents to injury sites.
Among the functions of reactive 
astrocytes, their roles in regulating brain 
inflammation have gained attention in 
recent years. Various stimuli present in 
the brain parenchymal microenvironment 
could promote astrocyte production of 
either pro- or anti-inflammatory mole-
cules that could exert effects on neighbor-
ing cells.3 Production of factors, such as B 
cell survival factor BAFF, CCL2, CCL5, 
CXCL10 and CXCL12, triggers adaptive 
immunity in the CNS. Astrocyte-derived 
GM-CSF, IL-6, CCL2 and CCL5 regu-
late migration, activation and prolifera-
tion of microglia. The inflammatory state 
with elevated levels of cytokines and che-
mokines also affects neuronal survival and 284  Oxidative Medicine and Cellular Longevity  Volume 3 issue 4
IL-1β, IL-6, IL-18 and colony-stimulat-
ing factors (CSF-1, -2, -3), have shown 
increased expression as early as 6 hours 
post-treatment. The most dramatic changes 
have been observed for IL-1α and IL-1β. In 
6 hours, about 11-fold and 23-fold changes 
were detected for IL-1α and IL-1β, respec-
tively. The increase in expression continues 
until 24 hours, resulting in 33-fold and 
76-fold changes, respectively. IL-1α and 
IL-1β are well-characterized proinflam-
matory cytokines, and, thus, the drastic 
increase in expression of these cytokines 
suggests a strong inflammatory response 
from astrocytes upon exposure to neuron-
derived α-synuclein. Other proinflamma-
tory cytokines induced in astrocytes by 
neuron-derived α-synuclein include IL-6, 
IL-18 and CSFs.
Another interesting observation was a 
significant decrease of TGFβ3 (by 80% 
after 24 hours) (Table 1). TGFβ is a well-
known anti-inflammatory molecule that 
acts to reduce synthesis and release of pro-
inflammatory cytokines and chemokines. 
TGFβ1 has been shown to reduce amyloid 
plaque load in mouse models of AD, pos-
sibly through increase of Aβ phagocytosis 
by microglia.
As shown in Table 1, mild increases 
in anti-inflammatory cytokines were also 
observed. IL-10 is a potent inhibitor of 
cytokines IL-1, -2, -6, -8, -12 and CSF1 
and chemokines, such as CCL3. IL-18 
binding protein (IL-18BP) is a soluble 
extracellular domain of the IL-18 receptor, 
which acts as a decoy receptor and binds 
circulating IL-18.17 Increased expression of 
IL-1 receptor type II (Il1r2) may counter-
act the action of IL-1β by prevention of 
binding to IL-1 receptor type I. However, 
these anti-inflammatory responses are late 
events and are much milder than the pro-
inflammatory responses.
Exposure to neuron-derived 
α-synuclein also caused dramatic changes 
in chemokine expression in astrocytes 
(Table 2). CC-type (CCL-3, -4, -5, -12,-
20), CXC-type (CXCL-1, -2, -5, -10, -11, 
-12, -16) and CX3C-type (CX3CL1) che-
mokines showed increased response to 
neuron-derived extracellular α-synuclein. 
These chemokines are involved in a vari-
ety of functions, such as recruitment of 
monocytes and macrophages, migra-
tion of microglia and neural progenitors, 
However, accumulating evidence supports 
critical involvement of α-synuclein in the 
pathogenesis of the disease. Aggregated 
forms of this protein are the major compo-
nent of Lewy bodies.7 Some rare familial 
forms of PD are linked to either missense 
or gene multiplication mutations in the 
α-synuclein gene.8 The α-synuclein 
gene locus has recently been identified 
as a major genetic risk factor for PD in 
genome-wide association studies of two 
large populations, one European and the 
other Japanese.9,10
α-Synuclein is a neuronal cytosolic 
protein. However, a small amount of this 
protein is released from neurons by uncon-
ventional exocytosis.11,12 Under various 
stress conditions, release of α-synuclein 
aggregates from neuronal cells was sig-
nificantly increased.11 Extracellular 
α-synuclein aggregates can be taken up by 
neurons and glial cells by endocytosis.13,14 
Inspired by these properties of α-synuclein, 
we have recently demonstrated that aggre-
gates of this protein can be transferred from 
one neuron to another through sequential 
exocytosis and endocytosis, forming Lewy 
body-like inclusions and leading to neuro-
nal death.15 This cell-to-cell transmission 
might be the mechanism underlying the 
propagation of Lewy body lesions during 
progression of PD.
In a recent study, we have shown that 
α-synuclein released from neuronal cells 
could also be transferred to and accumu-
late in astrocytes and induce expression 
of genes that are associated with immune 
functions.16 Conditioned medium of 
α-synuclein expressing SH-SY5Y neu-
ronal cells was treated to primary astro-
cyte cultures and the expression changes 
were monitored by microarray analysis. 
Of those genes that changed expression 
in response to extracellular α-synuclein, 
prominent changes were observed in genes 
for proinflammatory cytokines and che-
mokines, as shown in Tables 1 and 2.
Expression of Inflammatory  
Factors in Astrocytes Exposed  
to Neuron-derived α-Synuclein
Cytokines that are differentially expressed 
in astrocytes in response to extracellular 
α-synuclein are shown in Table 1. Many 
proinflammatory cytokines, such as IL-1α, 
many neuronal functions, such as synaptic 
transmission and plasticity.
Neuroinflammation in neurodegenera-
tive diseases, such as Alzheimer’s disease 
(AD) and Parkinson’s disease (PD), has 
been well-documented. In particular, an 
increased amount of proinflammatory 
cytokines, proliferation of glial cells and a 
reduction of neurotrophic factors derived 
from glial cells have been associated with 
PD.4 However, it is not known how neuro-
inflammatory responses are triggered and 
progress in neurodegenerative diseases. A 
series of recent works by our group and 
others suggests a novel mechanism of 
neuroinflammation in PD and the role 
of astrocytes in the inflammatory pro-
cess. In this Extra View, we would like 
to discuss how astrocytes modulate the 
inflammatory microenvironment in brain 
parenchyma in response to extracellular 
α-synuclein derived from neurons.
Parkinson’s Disease  
and α-synuclein
PD is the second most prevalent neu-
rodegenerative disease after AD, and is 
characterized primarily by movement 
abnormalities, such as resting tremor, bra-
dykinesia and muscle tone rigidity, and 
also by various psychiatric, autonomic 
and sensory dysfunctions.5 Pathologically, 
motor symptoms are attributed to selective 
loss of dopamine neurons in the substan-
tia nigra pars compacta region of the mid-
brain.5 In the same region, some surviving 
neurons contain proteinacious inclusion 
bodies known as Lewy bodies. Although 
much attention has been concentrated on 
the pathology of the midbrain, diverse 
clinical symptoms suggest affliction of 
multiple brain systems, and, indeed, Lewy 
body lesions are found in multiple areas of 
the cerebrum and brain stem. By analy-
sis of the patterns of Lewy body lesions 
in postmortem brains of PD patients, 
Braak and colleagues proposed a hypoth-
esis that as the disease progresses, Lewy 
bodies propagate in a highly predictable 
manner, initiating in the lower brain stem 
and olfactory bulb, spreading through 
the midbrain and mesocortex, and finally 
affecting wide areas of the neocortex.6
The mechanism underlying disease ini-
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microglia toxicity and suppress produc-
tion of pro-inflammatory cytokines from 
activated microglia.3 Production of these 
modulators with a precise spatiotemporal 
regulation may play an important role in 
fine-tuning of microglia activation.
Effects of Inflammatory Cytokines 
and Chemokines on Astrocytes
Cytokines and chemokines induced by 
extracellular  α-synuclein may directly 
target astrocytes. TNFα, IFNγ and IL-1 
are the main activators of astrocytes. 
Chemokines, such as CCL2, CCL5, 
CCL20, CXCL1, CXCL2 and CX3CL1, 
promote chemotaxis, cell proliferation 
and survival of astrocytes. CXCL12 and 
CCL5 induce glutamate release and syn-
thesis of cytokines and chemokines in 
astrocytes, implying a role in glia-glia 
and glia-neuron communications. An 
interesting observation was that unlike 
in microglia, changes in expression of 
receptors for these factors in response to 
extracellular α-synuclein were minimal in 
astrocytes (Tables 1 and 2). The reason 
for this may be that the main target for 
these inflammatory molecules produced 
by astrocytes is not astrocytes themselves, 
but microglia. Furthermore, astrocytes 
seem to downregulate some chemokine 
receptors, such as CXCR4 and increase 
expression of anti-inflammatory cytokine 
receptor IL-1 receptor type II (IL1r2), 
could be the major source of these inflam-
matory modulators, as recent advances 
have shown that astrocytes could pro-
duce many inflammatory cytokines and 
chemokines upon various stimuli. As we 
have described above, astrocytes exposed 
to neuron-derived α-synuclein induce 
production of proinflammatory cytokines 
and chemokines that can activate microg-
lia. Interestingly, in response to release of 
extracellular  α-synuclein from neuronal 
cells, microglia increased expression of 
receptors for cytokines and chemokines 
(unpublished data). These results indi-
cate that neuron-derived α-synuclein not 
only stimulates astrocytes for production 
of microglia-activating soluble factors, 
but also prepares microglia to respond 
to these factors. Inflammatory modula-
tors upregulated in astrocytes by extra-
cellular  α-synuclein regulate microglial 
chemotaxis, activation and prolifera-
tion.3 Therefore, by release of factors that 
recruit and activate microglia, astrocytes 
might act as an intermediary signal ampli-
fier, sensing neuron-derived extracellu-
lar  α-synuclein and relaying this signal 
to microglia for a potentially explosive 
inflammatory response.
Interestingly, some of the inflamma-
tory modulators expressed in astrocytes 
may have opposite effects on microglia. 
IL-10 may act on microglia to suppress 
inflammatory responses. Chemokines 
CX3CL1 and CCL5 are known to inhibit 
regulation of myelination, regulation of 
microglial activity, proliferation and sur-
vival of astrocytes and synaptic plasticity 
and transmission.3
Increased expression of cytokines and 
chemokines has also been detected in sev-
eral neurodegenerative diseases. Higher 
levels of TNFα, IL-1β, IL-2, IL-4, IL-6, 
TGFα, TGFβ1 and TGFβ2 have been 
shown in the brain parenchyma and CSF 
of human PD patients.18 Chemokines 
CCL2, CCL3, CCL5 and CCL8 and 
cytokines IL-1β, IFNγ and TNFα were 
increased in peripheral blood mono-
cytes of PD patients.19 CXCL12/CXCR4 
expression was increased in the nigros-
triatal system of PD, as well as in brain 
tumors, ischemia and HIV encephalitis.20
Effects on Microglia  
of Inflammatory Cytokines  
and Chemokines Released  
by Astrocytes
Microglia are the main immune respon-
sive cells in the CNS. These cells produce 
a large variety of inflammatory cytokines 
and chemokines, which could affect the 
parenchymal microenvironment in both 
auto- and paracrine fashion. Microglia 
could also receive inflammatory signals 
from neighboring astrocytes, neurons, 
endothelium and leukocyte infiltrates, as 
they express receptors for inflammatory 
modulators on the cell surface. Astrocytes 
Table 1. Changes in the cytokine and cytokine receptor mrNA expression in astrocytes by extracellular α-synuclein
Entrez ID
Gene 
symbol
Gene title
Fold changes p-value
6 hr 24 hr 6 hr 24 hr
pro-inflammatory
cytokines
24493 Il1α interleukin 1alpha 11.28 33.54 2E-07 2E-05
24494 Il1β interleukin 1beta 23.03 76.53 2E-07 1E-05
24498 Il6 interleukin 6 3.488 3.927 1E-05 3E-04
116472 Il17b PrEDiCtED: interleukin 17B 0.88 0.487 0.153 0.002
29197 Il18 interleukin 18 1.006 2.062 0.946 0.002
78965 Csf1 colony stimulating factor1 5.064 3.17 2E-06 3E-04
116630 Csf2 PrEDiCtED: colony stimulating factor2 2.85 6.194 7E-06 2E-04
25610 Csf3 colony stimulating factor3 1.256 3.8 0.001 3E-04
cytokine 
receptors
24499 Il6rα interleukin 6 receptor, alpha 1.588 2.371 1E-04 0.002
anti-inflammatory
cytokines
25325 Il10 interleukin 10 0.982 2.22 0.994 8E-04
84388 Il18bp interleukin 18 binding protein 1.057 2.092 0.121 0.002
25717 Tgfβ3 transforming growth factor, beta3 0.595 0.192 3E-04 4E-04
cytokine 
receptors
117022 Il1r2 interleukin 1 receptor, type ii 1.016 1.665 0.932 0.005286  Oxidative Medicine and Cellular Longevity  Volume 3 issue 4
On the other hand, chemokines, such as 
CXCL12 and CCL2, have a protective 
role by promoting migration and sur-
vival of neural precursors. As CX3CL1 
is a potent inhibitor of microglial neu-
rotoxicity, upregulation of constitu-
tively expressed CX3CL1 in astrocytes 
may protect neurons. It is also known 
to modulate evoked excitatory synap-
tic transmission.24 Therefore, changes 
in expression and secretion of cyto-
kines and chemokines by extracellular 
α-synuclein in astrocytes may have a 
significant effect on neuronal activity 
and survival in multifaceted ways.
neuronal functions, including neu-
rogenesis, neurotoxicity and synaptic 
transmission and plasticity. For exam-
ple, pro-inflammatory cytokines, such 
as IL-1 and TNFα, induce neurotrans-
mitter release in neurons. TGFβ3 is 
known to play a neuroprotective role 
in animal models of neurodegenera-
tion and also to induce dopaminergic 
neurogenesis.22,23 Therefore, reduction 
of TGFβ3 in response to extracellular 
α-synuclein (Table 1) may not only 
compromise anti-inflammatory func-
tion of astrocytes, but also leave neu-
rons more vulnerable to toxic insults. 
perhaps for negative feedback regulation. 
Other reports have also shown that astro-
cytes could survive inflammatory insults 
and death-receptor-induced apoptosis.3,21 
Therefore, astrocytes produce cytokines 
and chemokines that may act on astro-
cytes themselves; however, astrocytes may 
also activate the mechanism that restricts 
their own inflammatory responses.
Effects of Inflammatory Cytokines 
and Chemokines on Neurons
Inflammatory cytokines and chemo-
kines are known to regulate many 
Table 2. Changes in the chemokine and chemokine receptor mrNA expression in astrocytes by extracellular α-synuclein
Entrez ID
Gene 
 symbol
Gene title
Fold changes p-value
6 h 24 h 6 h 24 h
Chemokines
24770 Ccl2 chemokine (C-C motif) ligand 2 1.267 5.213 0.0012 0.0003
25542 Ccl3 chemokine (C-C motif) ligand 3 18.01 40.43 3E-07 1E-05
116637 Ccl4 chemokine (C-C motif) ligand 4 5.591 34.61 2E-06 2E-05
81780 Ccl5 chemokine (C-C motif) ligand 5 13.56 154.1 4E-07 4E-06
287910 Ccl6 chemokine (C-C motif) ligand 6 1.028 1.685 0.5854 0.0051
287561 Ccl7 chemokine (C-C motif) ligand 7 3.013 11.54 4E-06 3E-05
287562 Ccl12 PrEDiCtED: chemokine (C-C motif) ligand 12 1.455 78.03 0.0012 1E-05
362506 Ccl19 PrEDiCtED: chemokine (C-C motif) ligand 19 1.087 3.956 0.0193 0.0003
29538 Ccl20 chemokine (C-C motif) ligand 20 120.2 349.2 2E-08 2E-05
81503 Cxcl 1 chemokine (C-x-C motif) ligand 1 19.6 39.27 4E-08 0.0002
114105 Cxcl 2 chemokine (C-x-C motif) ligand 2 32.85 18.17 5E-08 5E-05
360918 Cxcl 4 chemokine (C-x-C motif) ligand 4 1.352 4.232 0.0302 0.0003
60665 Cxcl 5 PrEDiCtED: chemokine (C-x-C motif) ligand 5 52.5 249.5 1E-08 2E-06
246759 Cxcl 9 chemokine (C-x-C motif) ligand 9 1.212 3.885 0.0012 0.0005
245920 Cxcl 10 chemokine (C-x-C motif) ligand 10 10.36 12.47 4E-06 6E-05
305236 Cxcl 11 chemokine (C-x-C motif) ligand 11 4.762 33.66 2E-05 3E-05
24772 Cxcl 12 chemokine (C-x-C motif) ligand 12 1.249 4.094 0.0289 0.0003
497942 Cxcl 16 similar to chemokine (C-x-C motif) ligand 16 4.033 13.27 9E-06 5E-05
89808 Cx3cl1 chemokine (C-x3-C motif) ligand 1 9.005 24.16 2E-07 5E-05
- Xcl1 small inducible cytokine subfamily C, member 1 2.646 2.698 3E-05 0.0009
Chemokine 
receptors
57301 Ccr1 chemokine (C-C motif) receptor 1 0.969 0.928 0.9487 0.2708
60463 Ccr2 chemokine (C-C motif) receptor 2 1.09 0.978 0.1826 0.7404
117027 Ccr3 chemokine (C-C motif) receptor 3 0.976 0.834 0.6092 0.2104
171054 Ccr4 chemokine (C-C motif) receptor 4 0.995 1.026 0.9553 0.9216
117029 Ccr5 chemokine (C-C motif) receptor 5 1.048 1.007 0.2268 0.7863
308163 Ccr6 chemokine (C-C motif) receptor 6 0.91 1.098 0.0109 0.1073
287673 Ccr7 chemokine (C-C motif) receptor 7 0.987 0.829 0.965 0.5081
282832 Ccr9 chemokine (C-C motif) receptor 9 0.951 0.926 0.6239 0.0994
60628 Cxcr4 chemokine (C-x-C motif) receptor 4 0.58 0.383 0.0003 0.0007
84475 Cxcr3 chemokine (C-x-C motif) receptor 3 1.115 1.037 0.0893 0.7357
171056 Cx3cr1 chemokine (C-x3-C) receptor 1 1.036 0.958 0.3237 0.993
- Xcr1 PrEDiCtED: chemokine (C motif) receptor 1 1.034 0.959 0.2971 0.8277www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  287
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Conclusions
Based on our gene expression profiling 
study16 and other recent studies, we pro-
pose a working model for the α-synuclein-
mediated neuroinflammation process   
(Fig. 1). Neurons under stress release 
increased amounts of α-synuclein into the 
extracellular space. Released α-synuclein 
proteins then induce inflammatory 
responses from neighboring glia. As many 
recent studies have shown, microglia, 
the major immune cells in the CNS, can 
be directly activated by α-synuclein. 
Microglia activation can also be achieved 
indirectly by activation of astrocytes. 
Astrocytes, upon stimulation by neuron-
derived α-synuclein, synthesize and release 
a number of proinflammatory cytokines 
and chemokines that can in turn recruit 
and activate microglia. Therefore, through 
triggering the production of inflammatory 
factors in astrocytes, the effects of small 
amounts of α-synuclein protein released 
from neurons can be amplified and sus-
tained, thereby establishing an inflam-
matory microenvironment and further 
damaging neurons. On the other hand, 
some factors released from α-synuclein-
stimulated astrocytes have neuroprotective 
functions. Thus, it is tempting to speculate 
that astrocytes may act as a key modulator, 
sensing the levels of α-synuclein proteins 
released from neurons; in some conditions, 
establishing a neuroprotective environ-
ment, but in other conditions, causing full-
blown inflammation. Investigation of the 
role of astrocytes in α-synuclein-mediated 
neuroinflammation would likely provide 
critical insight into the mechanisms of 
neuron-glia and glia-glia interactions in a 
parenchymal inflammatory microenviron-
ment in brains of PD and other related neu-
rodegenerative diseases.
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